Co-delivery of SN38 and SR717 activates cGAS-STING for near-infrared II image-guided chemoimmunotherapy
文献类型：期刊论文
| 作者 | Hou, Xiaowen1,2,3,4; Ren, Chunlin1,2,3,4; Zeng, Xiaodong2,3,4; Hu, Yukun1,2,3,4,5; Zhao, Yicheng1,2,3,4,5; Cheng, Yuxin1,5; Luo, Qiusi1,2,3,4,5; Ding, Taotao1,2,3,4,5; Qiao, Xue2,3,4,5; Liao, Yuqin1,2,3,4 |
| 刊名 | JOURNAL OF CONTROLLED RELEASE
 |
| 出版日期 | 2025-10-10 |
| 卷号 | 386页码:16 |
| 关键词 | cGAS-STING activation Immunotherapy NIR-II fluorescence imaging Long-circulating |
| ISSN号 | 0168-3659 |
| DOI | 10.1016/j.jconrel.2025.114129 |
| 英文摘要 | DNA-targeting chemotherapies can activate the stimulator of interferon genes (STING) pathway but elicit limited immune responses. We engineered 3P-SN38, a long-circulating nanoplatform enabling sustained, tumor-targeted SN38 delivery and NIR-II imaging. To further potentiate immune activation and minimize STING agonist toxicity, SR717 was co-encapsulated, forming 3P-SN38@SR717. 3P-SN38@SR717 induced immunogenic cell death and dendritic cell maturation in vitro, with combination therapy showing superior effects. In vivo, 3P-SN38@SR717 effectively activated the cGAS-STING pathway, enhancing anti-tumor immunity. Significant increases in the populations of CD8+ T cells, mature dendritic cells, and M1-type macrophages were observed, along with elevated levels of cytokines, including IL-6 and TNF-alpha. This integrated nanoplatform offers a promising approach for chemoimmunotherapy, enabling durable tumor control with reduced dosing and improved safety. |
| WOS关键词 | CANCER ; PATHWAY |
| 资助项目 | National Key R & D Program of China[2023YFC3605500] ; National Natural Science Foundation of China[22477129] ; National Natural Science Foundation of China[82273796] ; Shenzhen Science and Technology Research Grant[JCYJ20220530140605012] ; Shenzhen Science and Technology Research Grant[JCYJ20230807090100002] ; Shenzhen Science and Technology Research Grant[JCYJ20240813111300001] ; Guangdong Basic and Applied Basic Research Foundation[2023A1515012649] ; Taishan Scholar Project of Shandong Province[TSQN202306320] ; Tibet Autonomous Region Science and Technology Plan Project Key Project[XZ202301ZY0014G] ; Natural Science Foundation of Shandong Province[ZR2023MB085] ; Shandong Laboratory Program[SYS202205] ; The 2024 Science and Technology Planning Project of Lhasa[LSKJ202445] ; Special Supporting Funds for Leading Talents at or above the Provincial Level in Yantai |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001559042300004 |
| 出版者 | ELSEVIER |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/321351]  |
| 专题 | 国家级研究中心_原创新药研究全国重点实验室 |
| 通讯作者 | Xiao, Yuling |
| 作者单位 | 1.Wuhan Univ, Zhongnan Hosp, Sch Pharmaceut Sci, Dept Radiol, Wuhan 430071, Peoples R China 2.Chinese Acad Sci, State Key Lab Drug Res, Shanghai 201203, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China 4.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264117, Peoples R China 5.Wuhan Univ, Shenzhen Inst, Shenzhen 518057, Peoples R China 6.Tibet Univ, Med Coll, Lasa 850002, Peoples R China 7.Sichuan Univ, Key Lab Drug Targeting & Drug Delivery Syst, Sichuan Engn Lab Plant Sourced Drug, Educ Minist, Chengdu 610041, Peoples R China 8.Sichuan Univ, Sichuan Res Ctr Drug Precis Ind Technol, West China Sch Pharm, Chengdu 610041, Peoples R China |
| 推荐引用方式 GB/T 7714 | Hou, Xiaowen,Ren, Chunlin,Zeng, Xiaodong,et al. Co-delivery of SN38 and SR717 activates cGAS-STING for near-infrared II image-guided chemoimmunotherapy[J]. JOURNAL OF CONTROLLED RELEASE,2025,386:16. |
| APA | Hou, Xiaowen.,Ren, Chunlin.,Zeng, Xiaodong.,Hu, Yukun.,Zhao, Yicheng.,...&Xiao, Yuling.(2025).Co-delivery of SN38 and SR717 activates cGAS-STING for near-infrared II image-guided chemoimmunotherapy.JOURNAL OF CONTROLLED RELEASE,386,16. |
| MLA | Hou, Xiaowen,et al."Co-delivery of SN38 and SR717 activates cGAS-STING for near-infrared II image-guided chemoimmunotherapy".JOURNAL OF CONTROLLED RELEASE 386(2025):16. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。